1-20 of 22
Wei Wei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He, YeXing Huang, ZeFeng Du, ZhiCheng Lai, Hanyue Ouyang, JingXian Shen, DongSheng Wen, QiJiong Li, YaoJun Zhang, Wei Wei, MinShan Chen, Li Xu, Anna Kan, Ming Shi
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-23-0060
Published: 02 November 2023
View article titled, Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Open the PDF for Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC) in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF8.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 22 August 2023
View article titled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma

Brooke Horowitch, Daniel Y. Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet Kluger, David L. Rimm, Jeffrey J. Ishizuka
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2908–2918.
https://doi.org/10.1158/1078-0432.CCR-23-0215
Published: 01 August 2023
View article titled, Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Open the PDF for Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4757–4767.
https://doi.org/10.1158/1078-0432.CCR-21-0903
Published: 01 September 2021
View article titled, A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Open the PDF for A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Abstract P25: Prostate cancer and COVID-19 outcomes: Results from the Cleveland Clinic registry of COVID-19 and cancer patients

Scott J. Dawsey, Nathan A. Pennell, Christopher Lemmon, Amanda Nizam, Wei Wei, Timothy D. Gilligan, Moshe C. Ornstein, Shilpa Gupta
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): P25.
https://doi.org/10.1158/1557-3265.COVID-19-21-P25
Published: 15 March 2021
View article titled, Abstract P25: Prostate cancer and COVID-19 outcomes: Results from the Cleveland Clinic registry of COVID-19 and cancer patients
Journal Articles

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Jeffrey S. Morris, Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy, Justin Windham, Huiqin Chen, Zhimin Tong, Baili Zhang, Wei Wei, Manyam Ganiraju, Bradley M. Broom, Hector A. Alvarez, Alicia Mejia, Omkara Veeranki, Mark J. Routbort, Van K. Morris, Michael J. Overman, David Menter, Riham Katkhuda, Ignacio I. Wistuba, Jennifer S. Davis, Scott Kopetz, Dipen M. Maru
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 120–130.
https://doi.org/10.1158/1078-0432.CCR-20-2403
Published: 04 January 2021
View article titled, Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Open the PDF for Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting in another window
Includes: Supplementary data
Journal Articles

A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models

Wei Wei, Yuquan Lin, Zhihui Song, Wenming Xiao, Liqi Chen, Jiejing Yin, Yan Zhou, Stefan K. Barta, Michael Petrus, Thomas A. Waldmann, Yibin Yang
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4093–4106.
https://doi.org/10.1158/1078-0432.CCR-19-4137
Published: 03 August 2020
View article titled, A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models
Open the PDF for A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models in another window
Includes: Supplementary data
Journal Articles

Abstract PR12: Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC

Shuang Zhang, Sonia Iyer, Hao Ran, Wei Wei, Robert A. Weinberg, Benjamin G. Neel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR12.
https://doi.org/10.1158/1557-3265.OVCA19-PR12
Published: 01 July 2020
View article titled, Abstract PR12: Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC
Journal Articles

Abstract A65: Spatial characterization of drug resistance in ovarian cancer

Kathleen I. Pishas, Elizabeth L. Christie, Jessica A. Beach, Kathryn Alsop, Alison Freimund, Nidhi Vashistha, Niyati Jhaveri, Emerald Doolittle, Wei Wei, Bingqing Zhang, Xiao-Jun Ma, David D.L. Bowtell
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A65.
https://doi.org/10.1158/1557-3265.OVCA19-A65
Published: 01 July 2020
View article titled, Abstract A65: Spatial characterization of drug resistance in ovarian cancer
Journal Articles

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer

Xianyu Zhang, Weiwei Zhao, Wei Wei, Zilong You, Xiaohua Ou, Mingming Sun, Yanling Yin, Xiaoyan Tang, Zhen Zhao, Changming Hu, Feifei Liu, Junhao Deng, Linlin Mao, Danyan Zhou, Yuxia Ren, Xiaoxia Li, Shangfei Zhang, Chang Liu, Jingshu Geng, Guodong Yao, Bingbing Song, Yupeng Liu, Dalin Li, Yongdong Jiang, Yanbo Chen, Yashuang Zhao, Shihui Yu, Da Pang
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6546–6553.
https://doi.org/10.1158/1078-0432.CCR-18-4055
Published: 01 November 2019
View article titled, Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer
Open the PDF for Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

Anjali S. Advani, Brenda Cooper, Valeria Visconte, Paul Elson, Ricky Chan, Jennifer Carew, Wei Wei, Sudipto Mukherjee, Aaron Gerds, Hetty Carraway, Aziz Nazha, Betty Hamilton, Ronald Sobecks, Paolo Caimi, Benjamin Tomlinson, Ehsan Malek, Jane Little, Alexander Miron, John Pink, Jaroslaw Maciejewski, Allison Unger, Matt Kalaycio, Marcos de Lima, Mikkael A. Sekeres
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4231–4237.
https://doi.org/10.1158/1078-0432.CCR-18-3886
Published: 15 July 2019
View article titled, A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Open the PDF for A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia in another window
Journal Articles

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Pok Fai Wong, Wei Wei, James W. Smithy, Balazs Acs, Maria I. Toki, Kim R.M. Blenman, Daniel Zelterman, Harriet M. Kluger, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2442–2449.
https://doi.org/10.1158/1078-0432.CCR-18-2652
Published: 15 April 2019
View article titled, Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
Open the PDF for Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract NTOC-113: TGF–β SIGNALING INHIBITION AS A POTENTIAL APPROACH TO TARGET SUBOPTIMALLY DEBULKED OVARIAN TUMORS

Wei Wei, Michael J. Birrer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-113.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-113
Published: 31 May 2017
View article titled, Abstract NTOC-113: TGF–β SIGNALING INHIBITION AS A POTENTIAL APPROACH TO TARGET SUBOPTIMALLY DEBULKED OVARIAN TUMORS
Journal Articles

Abstract TMEM-040: TUMOR ASSOCIATED MACROPHAGES MEDIATES THE ONCOGENIC EFFECT OF FGF18 IN OVARIAN CANCER

Wei Wei, Michael J. Birrer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): TMEM-040.
https://doi.org/10.1158/1557-3265.OVCASYMP16-TMEM-040
Published: 31 May 2017
View article titled, Abstract TMEM-040: TUMOR ASSOCIATED MACROPHAGES MEDIATES THE ONCOGENIC EFFECT OF FGF18 IN OVARIAN CANCER
Journal Articles

Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array

Vinod Vathipadiekal, Victoria Wang, Wei Wei, Levi Waldron, Ronny Drapkin, Michael Gillette, Steven Skates, Michael Birrer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (21): 4960–4969.
https://doi.org/10.1158/1078-0432.CCR-14-3173
Published: 01 November 2015
View article titled, Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Open the PDF for Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array in another window
Includes: Supplementary data
Journal Articles

Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma

Young Shik Shin, Wei Wei, Beatrice Gini, Paul Mischel, James Heath
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): PR09.
https://doi.org/10.1158/1557-3265.PMS14-PR09
Published: 13 February 2015
View article titled, Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma
Journal Articles

Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009

Rakhshandra Talpur, Lotika Singh, Seema Daulat, Ping Liu, Sarah Seyfer, Tanya Trynosky, Wei Wei, Madeleine Duvic
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5051–5060.
https://doi.org/10.1158/1078-0432.CCR-12-0604
Published: 16 September 2012
View article titled, Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009
Open the PDF for Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 in another window
Journal Articles

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3901–3911.
https://doi.org/10.1158/1078-0432.CCR-11-2088
Published: 15 July 2012
View article titled, GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O'Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3670–3683.
https://doi.org/10.1158/1078-0432.CCR-09-2828
Published: 14 July 2010
View article titled, Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

Gonzalo Lopez, Juehui Liu, Wenhong Ren, Wei Wei, Suizhao Wang, Guy Lahat, Quan-Sheng Zhu, William G. Bornmann, David J. McConkey, Raphael E. Pollock, Dina C. Lev
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3472–3483.
https://doi.org/10.1158/1078-0432.CCR-08-2714
Published: 18 May 2009
View article titled, Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
Open the PDF for Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma in another window